This event was canceled
Abstract: Hagen Triendl will discuss some crucial challenges when moving from benchmark datasets to a real world problem and how to overcome them, using drug discovery as application. In particular, he will discuss how to use machine learning to find new protein inhibitors in the lab.
Bio: Hagen Triendl is Head of Research at GTN Ltd., using machine learning to impact early stage drug discovery. Before joining GTN he worked in theoretical physics at CERN and Imperial College London.
18:30 - 19:00 Arrival and networking
19:00 - 20:00 Presentation and Q&A